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Abstract 30 
Context 31 
Oxidative stress is implicated in the development of microvascular disease and is associated with 32 
an upregulation of vascular endothelial growth factor (VEGF) which is pathogenetically linked 33 
to microvascular complications of diabetes. Patients of African origin have an increased 34 
susceptibility to microvascular kidney disease compared with Caucasians, the reasons and the 35 
mechanisms that contributes to this vulnerability are unclear.  36 
Objectives 37 
Primary) Investigate whether there are ethnic differences in Lipopolysaccharide induced 38 
monocyte VEGF production in whole blood cell cultures. Secondary) whether stimulated VEGF 39 
production is related to prevailing oxidative stress assessed by plasma lipid hydroperoxides 40 
(LOOH) and α-Tocopherol. 41 
Design and Setting 42 
Cross sectional study at a secondary care centre in North London, UK, serving an inner-city 43 
community of 154,000 adults.   44 
Patients 45 
African-Caribbean and Caucasian patients with type 2 diabetes (n=52) 46 
 47 
 48 
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Results 49 
Lipopolysaccharide induced production of VEGF in whole blood cultures (61.8[31.9] pg/mL to 50 
78.4[36.0] pg/mL; p<0.001) that correlated positively with LOOH levels (r=0.3, P=0.04) and was 51 
significantly higher in African-Caribbean than Caucasian type 2 diabetes patients (404 [207.5] vs 52 
268.8 [137.0] pg/mL X109/L monocytes; P=0.018). Plasma α-Tocopherol concentration was 53 
higher in Caucasian patients (40.3[18.3] vs 30.0[9.6] µmol/L; p=0.04) compared to African-54 
Caribbeans. 55 
Conclusions: 56 
This study suggests that the redox environment influences VEGF production in response to 57 
proinflammatory stimuli in type 2 diabetes. The differential responsiveness by ethnic origin may 58 
be of relevance in the variations in susceptibility to the long-term microvascular complications.  59 
 60 
  61 
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Introduction 62 
Diabetes mellitus affects more than 415 million individuals worldwide (1), the most common form 63 
is type 2 diabetes, that is characterized by persistent hyperglycaemia, the degree and the duration 64 
of which are well established as central in the development of vascular complications including 65 
diabetic kidney disease. This complication has a predilection for patients of African descent 66 
compared with Caucasian origin and is the leading cause of end stage renal disease (ESRD) (2). 67 
The incidence of ESRD related diabetes is four to six times higher in patients of African descent 68 
compared to Caucasians (3). 69 
 70 
It is understood that hyperglycaemia gives rise to the accumulation of advanced glycation end 71 
product proteins and reactive oxygen species which, together with their deficient disposal causes 72 
a metabolic imbalance known as oxidative stress (4, 5). In diabetic conditions, lipid hydroperoxide 73 
levels and histological damage of increased oxidative stress is increased in the kidney of animal 74 
models and can be reduced by antioxidant therapy (6, 7). The mechanisms related to free radical 75 
exposure that gives rise to tissue damage involves induction of pro-inflammatory pathways and 76 
cytokine release (8, 9). 77 
 78 
Reactive oxygen species upregulate vascular endothelial growth factor (VEGF) expression in 79 
various cell types, such as endothelial cells, smooth muscle cells, and macrophages (10, 11). 80 
Hohenstein et al (2006) reported increased VEGF expression by many different cell types in 81 
diabetic glomeruli compared to controls (12). VEGF increases the transcapillary leak of albumin 82 
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and therefore may contribute to microvascular disease. However, it is unknown if this mechanism 83 
is relevant to the enhanced risk of nephropathy seen in certain sub-groups of patients with diabetes. 84 
 85 
Meta-analysis studies showed that VEGF genetic polymorphisms are associated with increased 86 
risk of diabetic nephropathy in Asian and Caucasian patients (13, 14). We have previously reported 87 
ethnic differences in VEGF +405 polymorphism in patients with diabetes which has been shown 88 
to influence circulating levels of the cytokine (15). However, a genome-wide analysis has not 89 
shown consistent relationships between VEGF polymorphisms and circulating protein in different 90 
populations suggesting that other non-heritable, modulating factors contribute to differences in 91 
circulating levels (16). We reported increased oxidative stress in African-Caribbean patients with 92 
type 2 diabetes compared to Caucasian patients as assessed by lipid peroxidation product, 93 
antioxidant nutrients and antioxidant enzyme activities (17-19). The reasons for this observation 94 
or the mechanisms that could account for these differences are unclear. Therefore, we investigated 95 
the relationship of markers of oxidative stress and VEGF production in patients with type 2 96 
diabetes from different ethnic backgrounds.  97 
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Methods 98 
We studied 52 patients with type 2 diabetes who were part of the Prospective Evaluation of Early 99 
Nephropathy and its Treatment (PREVENT) study. Patients were considered to be of African-100 
Caribbean (AC) origin if both parents were native to either African or Caribbean countries. 101 
Caucasian (CA) white patients were native of Western European or Mediterranean countries.  102 
 103 
Individuals with a history of cardiovascular disease defined as having a clinical record of ischaemic 104 
heart disease (angina, myocardial infarction, coronary artery revascularization and or heart 105 
failure), peripheral vascular disease (intermittent claudication or peripheral artery 106 
revascularization) or cerebrovascular disease (transient ischaemic episodes or stroke), a history of 107 
malignancy or any other life threatening illness, current pregnancy, clinical proteinuria 108 
(albumin:creatinine ratio [ACR] >30 mg/mmol) or inter-current illness were excluded. 109 
Microalbuminuria was diagnosed if ACR was ≥ 3 and < 30mg/mmol in at least 2 of 3 sterile, early 110 
morning urine samples. Therapeutic regimens for hypertension and glucose lowering, and smoking 111 
history (as either current/ex-smoker or non-smoker) were recorded. The study was approved by 112 
the ethics committee of the Whittington Hospital Trust and all patients provided written, informed 113 
consent. 114 
 115 
Patients were studied in the post-prandial state after 12 hour fast. Body mass index (BMI) was 116 
calculated from weight in kg divided by height in m2. Sitting blood pressure was measured after 117 
10 minutes rest using a validated automated machine (OMRON 705HEM CP; OMRON 118 
Healthcare, West Sussex, U.K.) using an appropriate cuff size. Venous blood was taken from an 119 
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antecubital vein. Glycosylated haemoglobin A1c (HbA1c) was measured by a high-performance 120 
liquid chromatography system (Menarini 8140; Menarini Diagnostics, Wokingham, U.K.). Total 121 
cholesterol and total triglycerides were estimated using enzymatic methods (Boehringer-122 
Mannheim, Mannheim, Germany). Low density lipoprotein-cholesterol was calculated using the 123 
formula 3/4 (Total cholesterol - HDL-cholesterol) mmol/l described by de Cordova (20).  Urinary 124 
albumin and creatinine were measured by immunoturbidimetry (Cobas Fara, Roche Diagnostics, 125 
Lewes, UK) and the Jaffe rate reaction methods, respectively.  126 
 127 
Plasma lipid hydroperoxide (LOOH) concentrations (range in non-diabetic subjects: 0.22-6.22 128 
µmol/L) was measured by ferrous oxidation-xylenol orange (FOX-2) assay in conjunction with 129 
triphenylphosphine method (21). The inter- and intra-assay coefficients of variation (CV) of the 130 
FOX-2 assay are <5 and <6%, respectively. Plasma α-tocopherol concentrations was measured by 131 
HPLC as previously described (17) and corrected for lipid profile with inter- and intra-assay 132 
coefficients of variation of 3%. Total monocyte and platelet counts were measured in whole venous 133 
blood (Advia 120, Bayer, Basingstoke, UK). 134 
 135 
Cell culture 136 
To measure cytokine production, whole blood cell cultures were incubated in triplicates with or 137 
without lipopolysaccharide (LPS) (25mg/mL) to activate monocytes (22). The inter- and intra-138 
assay CVs for VEGF are 6 and 8% respectively. Concentration of the main circulating 165 amino 139 
acid VEGF-A isoform in culture supernatants was determined using an enzyme-linked 140 
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immunosorbent assay (ELISA) kit, according to the manufacturer's protocol (R&D Systems Ltd, 141 
Abingdon, UK). 142 
 143 
Statistics 144 
Analyses were performed using Stata 14.2 (Stata Corp, Texas, USA). Continuous variables were 145 
compared using parametric or non-parametric tests according to their distribution. Categorical 146 
variables were compared using the Chi-squared or Fishers exact tests. Variables with skewed 147 
distribution were log transformed before analyses. At an alpha of 0.05, the study had 98% power 148 
to detect a 16 pg/ml increase in LPS-stimulated VEGF. The multivariate model was based upon 149 
inputting those variables that were significantly different between the groups and/or of biological 150 
relevance to VEGF release. All tests were 2-tailed and a p value <0.05 was accepted as being 151 
statistically significant. 152 
 153 
 154 
Results 155 
The African-Caribbean and Caucasian groups had similar chronological age, body mass index, 156 
systolic and diastolic blood pressure, fasting plasma glucose, glycated haemoglobin and 157 
cholesterols, and prevalence of retinopathy and microalbuminuria. There were more males in the 158 
African- Caribbean group and they tended to have a longer duration of diabetes in comparison to 159 
the Caucasian cohort. Whilst the latter were more likely to have a positive smoking history, higher 160 
triglyceride concentrations, monocyte and platelet counts (Table 1).  There were no statistically 161 
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significant differences in the proportions of patients in the African-Caribbean and Caucasian 162 
groups that were prescribed oral hypoglycaemic agents (Metformin and/or Sulphonylureas) or 163 
Insulin (48 vs 53 or 36 vs 25%;p=0.713) for blood glucose management, angiotensin converting 164 
enzyme inhibitors or angiotensin 2 receptor antagonists to lower blood pressure (44 vs 165 
50%;p=0.896) or HMG Co-A reductase inhibitors to lower cholesterol (43 vs 56%;p=1.00). 166 
 167 
Lipopolysaccharide significantly increased VEGF concentrations from 61.8[31.9] pg/mL to 168 
78.4[36.0] pg/mL; p<0.001. Plasma LOOH and LPS stimulated VEGF release corrected for 169 
monocyte count was significantly higher in African-Caribbean patients than Caucasian patients 170 
(Figure 1). Plasma LOOH correlated with VEGF concentration (rho=0.3; p=0.04). Plasma α-171 
Tocopherol concentration was higher in a subset of a group (n=19) of the Caucasian patients 172 
(40.3[18.3] vs 30.0[9.6] µmol/L; p=0.04) compared with group of African-Caribbean patients 173 
(n=15). In multivariate analysis, current and previous history of smoking, female gender, 174 
Caucasian ethnicity (with marginal significance) and age all had negative  coefficients. In this 175 
model, plasma LOOH remained the only statistically significant independent predictor (Table 2). 176 
 177 
Discussion 178 
Our study has found that in patients with type 2 diabetes mellitus, the production of VEGF from 179 
LPS stimulated whole blood cell cultures is higher and proportional to biochemical evidence of 180 
greater exposure to oxidative stress in patients of African-Caribbean compared with Caucasian 181 
origin. These findings are consistent with in vitro studies showing the induction of VEGF by LPS 182 
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in monocytes and its upregulation by superoxide radical generating systems in a time and dose-183 
dependent manner (23).  184 
 185 
A circulating, cellular source of VEGF most notably, appears to have an important role in the 186 
reparation of ischaemic tissues. In animal models of myocardial ischaemia, restoration of blood 187 
flow and preservation of function is associated with VEGF protein production and VEGF receptor 188 
gene expression (24, 25). Studies in humans with myocardial infarction have shown that 189 
circulating VEGF is elevated and the VEGF gene upregulated during the acute phase of injury in 190 
both arterial smooth muscle cells and infiltrating macrophages (26, 27). Furthermore, after acute 191 
cerebral infarction elevation of circulating VEGF occurs in relation to the size of the lesion and 192 
the associated leucocytes (28).  Leucocytes, which can be less populous in people of African origin, 193 
have the same relationship with low-grade inflammation and cardio-metabolic risk seen in other 194 
ethnic groups with higher counts (29). However, the differences in VEGF response we observed 195 
suggests that monocyte function may be modified by the higher levels of glucose-induced 196 
oxidative stress that occurs in the patients of African-Caribbean origin.   197 
 198 
Monocyte-derived, VEGF plays a key role in chronic vascular disease of significance to 199 
vasculopathy in diabetes (30).  Increasing evidence implicates increased tissue production of 200 
VEGF in the development of diabetic retinopathy. In this context, increased expression of VEGF 201 
in the retina and raised levels in the aqueous occur in relation to hypoxia resulting in deleterious 202 
angiogenesis (31-33). Circulating VEGF may be a marker of future renal disease in patients with 203 
diabetes (34). The vascular permeability enhancing effects of VEGF may play a role in the rise in 204 
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urinary albumin excretion. Albuminuria in turn mediates release of other proinflammatory 205 
cytokines (35). In the evolution of diabetic nephropathy, monocytic infiltration is a feature of the 206 
development of tubulo-interstitial lesions. Therefore, oxidative stress induced VEGF could 207 
participate in the cascade of albuminuria, upregulation of chemoattractant molecules, increased 208 
monocyte attraction and trafficking of proinflammatory molecules and fibrogenic cytokines such 209 
as transforming growth factor β1 within the kidney. In a streptozotocin murine model of diabetes, 210 
increased podocyte VEGF signalling has been shown to significantly worsen the characteristic 211 
histological features of nephropathy (36). Lee at al reported that in cultured murine podocytes, 212 
glucose-dependent increases in oxidative stress and VEGF could be completely ameliorated by 213 
different antioxidants (37).  Moreover, it has been reported that the renal changes associated with 214 
the db/db model of diabetes could be abrogated by neutralising anti-VEGF antibody (38).  In 215 
addition, VEGF receptor tyrosine kinase inhibitor (SU5416) reduced albuminuria in type 2 216 
diabetes db/db mouse model (39), supporting the involvement and interplay of increased oxidative 217 
stress with VEGF in the pathogenesis of diabetic nephropathy. An association between high 218 
circulating levels of VEGF and the oxidative effects of ferritin suggests that both have a role in 219 
the development of complications in patients with diabetes (40).  Also, a recently described 220 
association between advanced chronic kidney disease and VEGF implies that it may also have a 221 
role in renal disease progression (41). 222 
 223 
In our study, it would appear that oxidative stress that determined the VEGF response to the 224 
inflammatory stimulus may be a proxy for ethnic origin. Exposure to hyperglycaemia though is 225 
a possible explanation of the differences in redox status between the groups (42). Duration 226 
of diabetes was significantly longer in univariate analysis in the African-Caribbean group 227 
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which however, failed to reach statistical significance as independent predictor in 228 
multivariate analysis.  Dietary factors could be relevant and it is notable that a survey from 229 
the United States suggests that 40% of minority ethnic groups with diabetes have a deficient 230 
micronutrient intake including vitamin E (43). A limitation of our study was that we did not collect 231 
dietary details from our cohort so we were not able to determine whether the differences in 232 
oxidative stress between the groups were related to the intake of vitamin E.   In summary, we show 233 
that a variation in VEGF production by activated, pro-inflammatory cells is related to ambient 234 
oxidative stress. Infiltrating monocytes contribute to renal disease and these findings may have 235 
relevance to differing susceptibility to ESRD. Further clinical studies are required to examine the 236 
role of circulating monocyte VEGF production in the renal complications of diabetes.    237 
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Legend 386 
Table 1. Demographic, clinical, biochemical and haematological characteristics of African-387 
Caribbean and Caucasian patients with type 2 diabetes 388 
 389 
Table 2. Multivariate regression analysis with LPS-stimulated VEGF release corrected for 390 
monocyte as the dependent variable 391 
 392 
Figure 1. Fasting mean (SEM), plasma lipid hydroperoxide (LOOH) in open bars, and vascular 393 
endothelial growth factor (VEGF) in solid bars, after stimulation with lipopolysaccharide 394 
corrected for monocyte count in whole blood cell cultures from patients of African- Caribbean 395 
(AC) and Caucasian (CA) origin with type 2 diabetes 396 
 397 
 398 
 399 
Demographic, clinical 
biochemical and haematological 
parameters 
African-Caribbean 
(n=22) 
Caucasian 
(n=30) 
 
p 
Age (years) 63.0 ± 6.4 59.0 ± 10.4 0.12 
Duration of diabetes 13.0 ± 9.5 8.3 ± 6.4 0.04 
BMI (Kg/m2) 28.8 ± 2.8 29.8 ± 5.6 0.47 
Systolic blood pressure(mmHg) 158.9 ± 17.8 153.8 ± 25.8 0.44 
Diastolic blood pressure (mmHg) 
Gender (Male/Female) % 
90.9 ± 8.2 
57/43 
87.4 ± 11.9 
32/68 
0.56 
0.08 
Smoking History (%)    
     Current 9 11  
     Previous  27 49 0.005 
     Never 64 40  
Microalbuminuria (%)  40 36 0.79 
Total Cholesterol (mmol/L) 5.3 ± 0.8 5.4 ± 0.8 0.51 
LDL-cholesterol (mmol/L) 2.2 ± 0.59 2.6 ± 0.91 0.06 
HDL-cholesterol (mmol/L) 1.61 ± 0.48 1.35 ± 0.56 0.07 
Triglycerides (mmol/L) 1.3 ± 0.5 1.8 ± 0.9 0.03 
Fasting plasma glucose (mmol/l) 9.2 ± 3.8 10.9 ± 4.6 0.18 
Table 1 Click here to download Table Demographic.doc 
1 Data expressed as Mean ± SD 
                                                          
1 Table 1. Demographic, clinical, biochemical and haematological characteristics of African-Caribbean and 
Caucasian patients with type 2 diabetes patients 
HbA1c (%) 8.3 ± 0.9 7.8 ± 1.8 0.21 
Platelet count (x109/L) 
Monocyte count (x109/L) 
196.9 ± 57.9 
0.21 ± 0.1 
236.8 ± 74.5 
0.36 ± 0.17 
0.07 
0.001 
Variable -coefficient t P value 95% CI 
Log10 LOOH 167.23 3.67 <0.001 75.6 to 258.9 
Gender -7.12 -0.45 0.66 -39.3 to 25.0 
Current Smoker -25.62 -0.98 0.33 -78.2 to 27.0 
Previous Smoker -33.63 -1.96 0.06 -68.1 to 0.8 
Ethnicity -24.36 -1.44 0.16 -58.4 to 9.6 
Duration Diabetes -1.43 -1.84 0.07 -3.0 to 0.1 
Log10 triglyceride -0.17 -0.31 0.76 -1.3 to 0.9 
 
 
1 
                                                     
1 Table 2. Multivariate regression analysis with increase in VEGF release corrected for monocyte count as the 
dependent variable  
Table Click here to download Table JCEM Final Table 2
Reviewed.docx
Figure 1 Click here to download Figure Figure1.tif 
